This is a preview of subscription content, log in via an institution to check access.
Data availability
For original data, please contact lijian@pumch.cn.
References
Li J, Duan MH, Wang C, Huang XF, Zhang W, Cao XX, et al. Impact of pretransplant induction therapy on autologous stem cell transplantation for patients with newly diagnosed POEMS syndrome. Leukemia. 2017;31:1375–81.
D’Souza A, Lacy M, Gertz M, Kumar S, Buadi F, Hayman S, et al. Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experience. Blood. 2012;120:56–62.
Kawajiri-Manako C, Sakaida E, Ohwada C, Miyamoto T, Azuma T, Taguchi J, et al. Efficacy and long-term outcomes of autologous stem cell transplantation in POEMS syndrome: a nationwide survey in Japan. Biol Blood Marrow Transpl. 2018;24:1180–6.
Cook G, Iacobelli S, van Biezen A, Ziagkos D, LeBlond V, Abraham J, et al. High-dose therapy and autologous stem cell transplantation in patients with POEMS syndrome: a retrospective study of the Plasma Cell Disorder sub-committee of the Chronic Malignancy Working Party of the European Society for Blood & Marrow Transplantation. Haematologica. 2017;102:160–7.
Dispenzieri A. POEMS syndrome: 2021 Update on diagnosis, risk-stratification, and management. Am J Hematol. 2021;96:872–88.
Kourelis TV, Buadi FK, Gertz MA, Lacy MQ, Kumar SK, Kapoor P, et al. Risk factors for and outcomes of patients with POEMS syndrome who experience progression after first-line treatment. Leukemia. 2016;30:1079–85.
Li J, Huang XF, Cai QQ, Wang C, Cai H, Zhao H, et al. A prospective phase II study of low dose lenalidomide plus dexamethasone in patients with newly diagnosed polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome. Am J Hematol. 2018;93:803–9.
Cai Q-Q, Wang C, Cao X-X, Cai H, Zhou D-B, Li J. Efficacy and safety of low-dose lenalidomide plus dexamethasone in patients with relapsed or refractory POEMS syndrome. Eur J Haematol. 2015;95:325–30.
Suichi T, Misawa S, Nagashima K, Sato Y, Iwai Y, Katayama K, et al. Lenalidomide treatment for thalidomide-refractory POEMS syndrome: a prospective single-arm clinical trial. Intern Med. 2020;59:1149–53.
Ohwada C, Sakaida E, Kawajiri-Manako C, Nagao Y, Oshima-Hasegawa N, Togasaki E, et al. Long-term evaluation of physical improvement and survival of autologous stem cell transplantation in POEMS syndrome. Blood. 2018;131:2173–6.
Shibamiya A, Ohwada C, Ishii A, Mishina T, Nagai Y, Hino Y, et al. Successful second autologous stem-cell transplantation for patients with relapsed and refractory POEMS syndrome. Bone Marrow Transpl. 2021;56:517–20.
Acknowledgements
This work was supported by institutional research funding provided by the CAMS Innovation Fund for Medical Sciences (Grant No. 2021-1-I2M-019, for LJ) and the National High Level Hospital Clinical Research Funding (2022-PUMCH-C-051, for LJ).
Author information
Authors and Affiliations
Contributions
A-aL and Y-yY designed the study, collected and analyzed the data, and drafted and revised the manuscript; X-mG and HZ collected data; X-xC, LZ, and D-bZ recruited patients and collected data; and JL designed the study, recruited patients, and drafted and revised the text.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Li, Aa., Yu, Yy., Gao, Xm. et al. Treatment and outcome of second-line therapy for POEMS syndrome after autologous stem cell transplantation. Bone Marrow Transplant 58, 1167–1169 (2023). https://doi.org/10.1038/s41409-023-02047-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41409-023-02047-8
- Springer Nature Limited